Open AccessRandomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)
Author(s) -
Tufia C. Haddad,
Jun He,
Ciara C. O’Sullivan,
Beiyun Chen,
Donald W. Northfelt,
Amylou C. Dueck,
Karla V. Ballman,
Kathleen Tenner,
Hannah M. Linden,
Joseph A. Sparano,
Judith O. Hopkins,
Chamath De Silva,
Edith A. Perez,
Paul Haluska,
Matthew P. Goetz
Publication year - 2021
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-021-06221-8
Subject(s) - capecitabine , lapatinib , medicine , adverse effect , trastuzumab , oncology , breast cancer , metastatic breast cancer , cohort , cancer , colorectal cancer
To compare efficacy and safety of capecitabine and lapatinib with or without IMC-A12 (cituxumumab) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.